Insulet Co. (NASDAQ:PODD) Shares Sold by Panagora Asset Management Inc.

Panagora Asset Management Inc. lowered its stake in shares of Insulet Co. (NASDAQ:PODD) by 2.1% in the first quarter, HoldingsChannel reports. The fund owned 2,889 shares of the medical instruments supplier’s stock after selling 61 shares during the quarter. Panagora Asset Management Inc.’s holdings in Insulet were worth $921,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Insulet by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 6,203,941 shares of the medical instruments supplier’s stock worth $1,652,668,000 after buying an additional 58,932 shares during the last quarter. Clearbridge Investments LLC increased its position in shares of Insulet by 38.8% in the first quarter. Clearbridge Investments LLC now owns 1,696,822 shares of the medical instruments supplier’s stock worth $452,016,000 after acquiring an additional 474,545 shares in the last quarter. Moneta Group Investment Advisors LLC raised its stake in shares of Insulet by 101,333.5% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,300,377 shares of the medical instruments supplier’s stock valued at $382,818,000 after acquiring an additional 1,299,095 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Insulet by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 956,799 shares of the medical instruments supplier’s stock valued at $281,338,000 after acquiring an additional 30,712 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in Insulet by 5.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 616,690 shares of the medical instruments supplier’s stock valued at $134,402,000 after purchasing an additional 30,411 shares in the last quarter.

Insulet Stock Down 7.7 %

PODD stock opened at $178.53 on Friday. The firm has a fifty day moving average price of $244.18 and a two-hundred day moving average price of $282.18. The company has a debt-to-equity ratio of 2.47, a current ratio of 3.34 and a quick ratio of 2.38. Insulet Co. has a 1-year low of $170.87 and a 1-year high of $335.91. The firm has a market cap of $12.46 billion, a price-to-earnings ratio of 200.60, a PEG ratio of 3.19 and a beta of 0.81.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Tuesday, August 8th. The medical instruments supplier reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.14. Insulet had a net margin of 4.29% and a return on equity of 22.42%. The firm had revenue of $396.50 million for the quarter, compared to analyst estimates of $383.97 million. Research analysts predict that Insulet Co. will post 1.64 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. decreased their target price on Insulet from $365.00 to $325.00 and set an “overweight” rating for the company in a research report on Wednesday, August 9th. UBS Group lowered their price objective on shares of Insulet from $270.00 to $215.00 and set a “neutral” rating for the company in a research report on Wednesday. Raymond James decreased their target price on shares of Insulet from $350.00 to $299.00 and set an “outperform” rating for the company in a research note on Wednesday, August 9th. Morgan Stanley dropped their price target on shares of Insulet from $343.00 to $208.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 24th. Finally, StockNews.com assumed coverage on shares of Insulet in a research report on Thursday, August 17th. They issued a “hold” rating for the company. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $286.67.

Insider Buying and Selling

In other Insulet news, SVP Dan Manea sold 175 shares of the stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $290.00, for a total value of $50,750.00. Following the sale, the senior vice president now directly owns 4,522 shares of the company’s stock, valued at $1,311,380. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Insulet news, CEO James Hollingshead purchased 5,550 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The shares were purchased at an average cost of $181.41 per share, with a total value of $1,006,825.50. Following the completion of the transaction, the chief executive officer now owns 34,177 shares of the company’s stock, valued at $6,200,049.57. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Dan Manea sold 175 shares of the firm’s stock in a transaction dated Tuesday, June 20th. The stock was sold at an average price of $290.00, for a total value of $50,750.00. Following the sale, the senior vice president now owns 4,522 shares of the company’s stock, valued at $1,311,380. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.